Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ML-007C-MA for hallucinations and delusions associated with Alzheimer's disease psychosis
2024-519820-26-00Phase 2Authorised
- Sponsor
- MapLight Therapeutics
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing ML-007C-MA with Placebo (2 arms). Primary endpoint: Change from baseline to Week 7 in NPI-C hallucinations and delusions score. Planned start Jan 2026; status: authorised.
02
Drugs
ML-007/PAC
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2024-519820-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519820-26-00.